The emergent highly pathogenic avian influenza A (H7N9) (HPAI) virus is a major public concern in China. Therefore, it is crucially important to develop an effective vaccine against this virus. In this study, we constructed a baculovirus vaccine expressing the hemagglutinin (HA) of H7N9 strain A/Chicken/Jiaxing/148/2014 (JX148). The recombinant baculovirus (rBac-JX148HA) generated in this study showed good growth in insect cells and good safety, and it stably expressed the HA protein. We compared the immunogenicity and efficacy of the inactivated whole-virus vaccine JX148 and rBac-JX148HA. One chicken in the JX148-treated group died on day 4 post-challenge, and three chickens had typical clinical symptoms (survival rate, 90%; morbidity, 40%). However, no chickens immunized with rBac-JX148HA showed clinical signs during the 14-day observation period. An analysis of viral shedding and viral replication demonstrated that rBac-JX148HA more efficiently inhibited viral shedding and viral replication than the inactivated whole-virus vaccine. Taken together, these results indicate that the inactivated recombinant baculovirus vaccine induces a high hemagglutination inhibition antibody titer, provides complete protection against challenge with the highly pathogenic H7N9 virus, and effectively inhibits viral shedding. Therefore, the candidate vaccine has potential utility in the prevention and control of H7N9 avian influenza and is also appropriate for veterinary vaccines using cell suspension culture technology.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00705-018-04142-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protective humoral immunity induced by virus-like particles expressing Toxoplasma gondii CST1 or MIC8.
Acta Trop
December 2024
Department of Medical Zoology, School of Medicine, Kyung Hee University, Seoul, 02447, Republic of Korea; Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, Core Re-search Institute (CRI), Kyung Hee University, Seoul, 02447, Republic of Korea. Electronic address:
Protective efficacy assessment of toxoplasmosis vaccines, at least at the preclinical level, frequently involves lethal dose challenge infection. Nonetheless, their efficacies remain largely unexplored against low infection doses which better reflects how humans become infected in the real world. In this study, we compared the immunity elicited in mice that were heterologously immunized with recombinant baculovirus and virus-like particles expressing either the cyst wall protein (CST1) or microneme protein 8 (MIC8) of Toxoplasma gondii (T.
View Article and Find Full Text PDFRole of ubiquitin-proteasome pathway in budded virus egress and GP64 surface distribution in Bombyx mori nucleopolyhedrovirus.
J Gen Virol
December 2024
Jiangsu Key Laboratory of Sericultural and Animal Biotechnology, School of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang 212100, PR China.
The Bombyx mori nucleopolyhedrovirus (BmNPV) is a DNA virus that affects the silkworm, , causing substantial economic losses in sericulture. This study investigates the mechanisms underlying budded virus egress, focusing on the roles of the ubiquitin-proteasome pathway (UPP) machinery. BmNPV produces two virion types: budded virions (BVs) and occlusion-derived virions (ODVs), which differ in their envelope origins and functions.
View Article and Find Full Text PDFConstruction with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H9N2 vaccine against heterologous virus.
Vet Microbiol
January 2025
National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control, Guangdong Provincial Key Laboratory of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, PR China; UK-China Centre of Excellence for Research on Avian Diseases, Guangzhou 510642, PR China. Electronic address:
Article Synopsis
- - The study aimed to improve the effectiveness of inactivated H9N2 avian influenza vaccines by combining them with a recombinant baculovirus containing multiple T and B cell epitopes, showing better immune response than using the vaccine alone.
- - Results indicated that the combined immunization led to significantly higher levels of antibodies and T cell responses, particularly after exposure to a heterologous virus, which suggests a robust immune boost.
- - The InV+BV-BNT group showed lower viral loads and virus positivity rates in samples taken after infection, highlighting its potential as a supplementary vaccine to enhance protection against H9N2 avian influenza.
Critical considerations for co-administering rivaroxaban and vonoprazan: Unveiling potential pharmacokinetic interactions.
Chem Biol Interact
December 2024
School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, PR China. Electronic address:
To study the effects of metabolic enzyme activity inhibition and genetic polymorphisms on the pharmacokinetics and pharmacodynamics of rivaroxaban, we established an in vitro enzymatic reaction system to screen for inhibitors, and used the UPLC-MS/MS method to detect the levels of rivaroxaban and its metabolite M2-1. Additionally, in vivo pharmacokinetic-pharmacodynamic studies were conducted using Sprague-Dawley rats. Human recombinant CYP2J2 baculosomes were prepared using a baculovirus-insect expression system to investigate the impact of genetic polymorphisms on rivaroxaban metabolism through enzyme kinetics methods.
View Article and Find Full Text PDFSingle dose of recombinant baculovirus vaccine expressing sigma B and sigma C genes provides good protection against novel duck reovirus challenge in ducks.
Poult Sci
November 2024
Key Laboratory of Avian Bioproducts Developmen, Ministry of Agriculture and Rural Affairs, China; Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonosis, Yangzhou University, Yangzhou, Jiangsu, China.
Article Synopsis
- The novel duck reovirus disease (NDRV) significantly impacts the waterfowl industry, and currently, there are no commercial vaccines available to combat this infection worldwide.
- Researchers developed two subunit vaccine candidates, σB and σC, using an insect cell-baculovirus expression system (IC-BEVS) to create these vaccines from recombinant viruses targeting NDRV.
- The study found that a single dose of either σB or σC protein improved immune response and overall health in ducklings better than a traditional whole virus vaccine, with the combination of both subunits showing especially strong protective effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!